Jin Medical International (ZJYL) Common Equity (2022 - 2025)

Jin Medical International has disclosed Common Equity across 4 years of filings, most recently posting $29.6 million for Q3 2025.

• Common Equity for Q3 2025 came in at $29.6 million, up 3.8% year-over-year; the trailing twelve-month figure through Sep 2025 was $29.6 million (up 3.8% YoY), and the FY2025 annual result was $29.6 million, up 3.8% from the prior year.
• Common Equity came in at $29.6 million for Q3 2025 at Jin Medical International, up from $27.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $29.6 million in Q3 2025 to a low of $15.2 million in Q3 2022.
• The 4-year median for Common Equity is $26.2 million (2024), against an average of $25.0 million.
• Across the five-year window, Common Equity surged 57.39% in 2023 and grew 3.8% in 2025, its largest moves.
• Jin Medical International's Common Equity stood at $15.2 million in 2022, then jumped by 57.39% to $24.0 million in 2023, then rose by 19.07% to $28.6 million in 2024, then climbed by 3.8% to $29.6 million in 2025.
• The last three Common Equity figures came in at $29.6 million (Q3 2025), $27.9 million (Q1 2025), and $28.6 million (Q3 2024), per Business Quant data.